Format

Send to

Choose Destination
Neurobiol Aging. 2018 Sep 8;73:21-29. doi: 10.1016/j.neurobiolaging.2018.09.001. [Epub ahead of print]

Blood acetylcholinesterase level is a potential biomarker for the early detection of cerebral amyloid deposition in cognitively normal individuals.

Author information

1
Department of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea; Neuroscience Research Institute, College of Medicine, Seoul National University, Seoul, Republic of Korea.
2
Department of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea.
3
Institute of Human Behavioral Medicine, Medical Research Center, Seoul National University, Seoul, Republic of Korea.
4
Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea.
5
Institute of Human Behavioral Medicine, Medical Research Center, Seoul National University, Seoul, Republic of Korea; Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea; Department of Psychiatry, College of Medicine, Seoul National University, Seoul, Republic of Korea. Electronic address: selfpsy@snu.ac.kr.
6
Department of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea; Neuroscience Research Institute, College of Medicine, Seoul National University, Seoul, Republic of Korea. Electronic address: inhee@snu.ac.kr.

Abstract

Cerebral β-amyloid (cAβ) deposition and cholinergic dysfunction have been considered as major pathological and functional hallmarks of Alzheimer's disease (AD). Acetylcholinesterase (AChE) is one of the major cholinergic enzymes, and there is no report to show the relationship between cAβ accumulation and peripheral AChE alteration in early stage of AD pathogenesis. Recent studies demonstrate that cAβ starts to deposit 15-20 years ahead of symptomatic appearance and this preclinical AD is important for early diagnosis of disease. In this study, we investigated the link between cAβ deposition and the peripheral AChE in cognitively normal (CN) individuals. A total of 407 individuals who underwent Pittsburgh compound B (PiB)-positron emission tomography participated in our study. Lower levels of plasma AChE and its enzymatic activity were detected in CN individuals with cAβ deposition than in those without cAβ. Plasma AChE levels and enzymatic activity were negatively correlated with the degree of cAβ deposition. Our results suggest that blood AChE can be used as a potential blood biomarker for the prediction of cAβ deposition in CN individuals.

KEYWORDS:

Acetylcholinesterase; Alzheimer's disease; Blood-based biomarker; Cerebral Aβ deposition; PiB-PET; β-amyloid

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center